Clinical Trial Update: Azeliragon in MGMT Unmethylated Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Azeliragon in MGMT unmethylated glioblastoma. The study is currently listed as active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Azeliragon (Azeliragon)

Snippet

Sponsor: Cantex Pharmaceuticals | Conditions: Glioblastoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING